Rio2 Limited has started a first-phase surface drilling program at its Condestable Copper Mine in Peru, aiming to explore copper-gold-silver mineralization with 85 drill holes planned. The company completed a large geophysical survey identifying six priority exploration targets in the district. Drilling at the Fenix Gold Mine in Chile is paused due to weather and safety, with plans to resume in January 2027 and an updated resource estimate expected by year-end. In Canada, Rio2 advanced the Kalzas Tungsten Project with geological mapping, permitting, and community engagement, planning a 2,000-metre scout drilling program in summer 2027 to further assess tungsten mineralization.
Rio2 Limited's exploration update coincides with a Basic Materials sector breadth of 38 US stocks on Pluang, where 17 rose and 19 fell as of Sep 22, 2026 18:51 WIB. Among notable movers, Southern Copper Corp (SCCO) rose 0.74% to USD 199.52 with a typical hold time of 59 days and a strong buy order activity of 98%. Dow Inc (DOW) and Avient Corporation (AVNT) both declined by 0.99%, with DOW showing 83% sell orders and a typical hold time of 81 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
